Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can the RSV vaccine protect the most vulnerable? new study aims to find out

NCT ID NCT07296120

Disease control Sponsor: The Cooper Health System Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the RSV vaccine Abrysvo can help blood cancer patients who have had a stem cell transplant or CAR-T therapy build immunity against RSV. Researchers will measure antibody levels before and after vaccination in 30 adults. The goal is to see if the vaccine triggers a strong enough immune response to prevent serious respiratory infections.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Respiratory Syncytial Virus Prefusion F Vaccine (RSVpreF, brand name Abrysvo)
What this could lead to
If it works, this could show that the RSV vaccine protects vulnerable blood cancer patients from severe respiratory infections after transplant or CAR-T therapy.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The vaccine may not produce a strong immune response in these patients due to their weakened immune systems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or older * Diagnosis of hematological malignancy * Treatment with HSCT or CAR-T therapy * Must be able to give informed consent * Must be willing to provide blood samples after HSCT or CAR-T therapy and prior to vaccination * Must be willing to provide blood samples at four weeks and six months post-vaccination * Must have an insurance plan that covers the cost of recieving the RSV vaccine. Exclusion Criteria: * History of a severe allergic reaction to any component of the RSV vaccine * Use of intravenous immunoglobulin (IVIG) for hypogammaglobulinemia within the past six months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bone marrow transplant - autologous or allogeneic are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm respiratory syncytial virus infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bone marrow transplant - autologous or allogeneic Car-T cell therapy RSV immunization

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cooper University Hospital

    Camden, New Jersey, 08103, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.